Almost every S&P/ASX 200 Index (ASX: XJO) sector opened in red on Monday.
Commodities are logging the heaviest losses, with the S&P/ASX Energy (INDEXASX: XEJ) and S&P/ASX Materials (INDEXASX: XMJ) down 2.12% and 2.36% respectively.
But amidst the sea of red, the S&P/ASX Health Care (INDEXASX: XHJ) is standing tall, up 2.06%.
Encouragingly, the resilient healthcare index is experiencing broad buying across the board, from heavyweight CSL Ltd (ASX: CSL) to Ansell Ltd (ASX: ANN).
Top performing ASX 200 healthcare shares today
CSL
The CSL share price has emerged as one of the best performing ASX 200 healthcare shares on Monday, lifting 2.49% to $284.63.
Unfortunately, CSL shares have struggled in the past month, losing 9% before today's rally.
Adding further insult to injury could be this broker downgrade, with Credit Suisse flagging potential margin weakness due to challenging plasma collection conditions.
Sonic Healthcare Ltd (ASX: SHL)
The Sonic Healthcare share price is another ASX 200 healthcare winner on Monday.
Shares in the medical diagnostic services company are rallying towards record territory, currently 1.37% higher to $39.62.
Sonic Healthcare has played an active role in the nation's COVID-19 testing, performing more than 18 million tests across 60 Sonic laboratories globally, according to its half-year results.
Resmed CDI (ASX: RMD)
The Resmed share price has gone from strength to strength after a stellar performance in June.
Resmed surged in mid-June following news that a competitor had to issue a major product recall for a number of its ventilator devices.
Resmed shares have added another 2.36% on Monday to $34.49, possibly looking at another record close.
The company announced the release of its fourth quarter results will be on Thursday, 5 August.
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Fisher & Paykel is another player in the respiratory device space that's pushing higher today.
At the time of writing, Fisher & Paykel shares are up 1.57% to $29.17.
Despite a small win today, Fisher & Paykel shares have struggled to find headway in 2021, down 5.53% year-to-date.
Alongside its underperformance, a broker note out of UBS flagged the company's earnings could be under pressure as a result of reduced COVID-19 hospitalisation rates.
